105
Participants
Start Date
March 26, 2021
Primary Completion Date
August 16, 2024
Study Completion Date
August 16, 2024
INCB099318
INCB099318 administered orally in 20 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle.
Karolinska University Hospital Solna, Solna
Turku University Hospital, Turku
Prisma Health Cancer Institute Faris, Greenville
Tampere University Hospital, Tampere
Vanderbilt-Ingram Cancer Center, Nashville
Sahlgrenska University Hospital, Gothenburg
Uppsala Universitet - Akademiska Sjukhuset, Uppsala
Hackensack University Medical Center, Hackensack
Universitair Ziekenhuis Brussel, Brussels
Institut Jules Bordet, Brussels
Universitair Ziekenhuis Antwerpen (Uza), Edegem
Ghent University Hospital, Ghent
Universitaire Ziekenhuis Leuven - Gasthuisberg, Leuven
Rigshospitalet Uni of Hospital of Copenhagen, Copenhagen
Helsinki University Central Hospital, Helsinki
Docrates Cancer Center, Helsinki
Haukeland University Hospital, Bergen
Oslo University Hospital, Oslo
Western General Hospital, Edinburgh
St James University Hospital, Leeds
Guys and St Thomas Nhs Foundation Trust, London
The Royal Marsden Hospital Nhs Trust London, London
Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London
Freeman Hospital Newcastle Upon Tyne Foundation Nhs Trust, Newcastle upon Tyne
Lead Sponsor
Incyte Corporation
INDUSTRY